These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 2252149)

  • 21. [Survival analysis in patients with cutaneous malignant melanoma].
    Radović-Kovacević V; Pekmezović T; Adanja B; Jarebinski M; Marinković J; Tomin R
    Srp Arh Celok Lek; 1997; 125(5-6):132-7. PubMed ID: 9265233
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Five-year overall survival and prognostic factors in patients with cervical cancer in Bulgaria.
    Kostova P; Zlatkov V; Danon S
    J BUON; 2008; 13(3):363-8. PubMed ID: 18979551
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Prognostic factors of common epithelial ovarian cancer treated by surgery and cisplatin based combination chemotherapy].
    Sasaki H; Ochiai K; Terashima Y; Mochizuki S; Soda T; Nishimura H; Yakushiji M; Hirabayashi M
    Gan No Rinsho; 1989 Oct; 35(13):1615-20. PubMed ID: 2585733
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Registry of patients with advanced ovary carcinoma in the province of Stara Zagora].
    Trifonov I
    Akush Ginekol (Sofiia); 2007; 46(7):35-8. PubMed ID: 18333420
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The prognostic significance of angiogenesis in epithelial ovarian carcinoma.
    Alvarez AA; Krigman HR; Whitaker RS; Dodge RK; Rodriguez GC
    Clin Cancer Res; 1999 Mar; 5(3):587-91. PubMed ID: 10100710
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Carcinoma of the ovary, stages I and II. A prospective randomized study of the effects of postoperative chemotherapy and radiotherapy.
    Sigurdsson K; Johnsson JE; Tropé C
    Ann Chir Gynaecol; 1982; 71(6):321-9. PubMed ID: 6297368
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Borderline and invasive epithelial ovarian tumors in young women.
    Carter J; Fowler J; Carlson J; Carson L; Twiggs LB
    Obstet Gynecol; 1993 Nov; 82(5):752-6. PubMed ID: 8414321
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Effort to radically cure stage III and IV esophageal carcinoma with simultaneous radiotherapy and chemotherapy in standard clinical practice].
    Farzad M; De Luca MC; Rubino G; Pirtoli L; Pepi F; Sebaste L; Ponticelli P; Atzeni G; Maranzano E; Silvano G
    Radiol Med; 2001; 102(1-2):72-7. PubMed ID: 11677442
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Combined treatment and prognostic analysis of advanced epithelial ovarian carcinoma].
    Huang X; Cai S; Fan J; Li Z
    Zhonghua Fu Chan Ke Za Zhi; 2002 May; 37(5):291-3. PubMed ID: 12133404
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-effective treatment of women with advanced ovarian cancer by cytoreductive surgery and chemotherapy directed by an in vitro assay for drug resistance.
    Orr JW; Orr P; Kern DH
    Cancer J Sci Am; 1999; 5(3):174-8. PubMed ID: 10367175
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Characterization and survival of patients with serous cystadenocarcinoma of the ovaries.
    Demopoulos RI; Bigelow B; Blaustein A; Chait J; Gutman E; Dubin N
    Obstet Gynecol; 1984 Oct; 64(4):557-63. PubMed ID: 6483302
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Clinical features and prognostic factors of malignant ovarian teratoma].
    Jin FM; Zhu GZ; Feng YJ
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2003 Aug; 25(4):427-30. PubMed ID: 12974088
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Survival of cervical cancer patients in selected regions of Poland in 1990-1996, in relation to some prognostic factors].
    Bielska-Lasota M; Krynicki R; Rabczenko D; Czerw-Głab K; Starzewski J; Wronkowski Z; Zieliński J; Chil A; Hudała-Klecha J; Swiercz A
    Przegl Epidemiol; 2004; 58(3):523-36. PubMed ID: 15730017
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Improvement of survival in sex cord stromal tumors - an observational study with more than 25 years follow-up.
    Hölscher G; Anthuber C; Bastert G; Burges A; Mayr D; Oberlechner E; Schubert-Fritschle G; Sinz S; Sommer H; Schmalfeldt B; Engel J;
    Acta Obstet Gynecol Scand; 2009; 88(4):440-8. PubMed ID: 19191075
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Compliance to clinical guidelines for early-stage epithelial ovarian cancer in relation to patient outcome.
    Sijmons EA; van Lankveld MA; Witteveen PO; Peeters PH; Koot VC; van Leeuwen JS
    Eur J Obstet Gynecol Reprod Biol; 2007 Apr; 131(2):203-8. PubMed ID: 16707204
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of adjuvant paclitaxel and carboplatin for advanced stage epithelial ovarian cancer: a population-based cohort study of all patients in western Sweden with long-term follow-up.
    Akeson M; Zetterqvist BM; Dahllöf K; Brännström M; Horvath G
    Acta Obstet Gynecol Scand; 2008; 87(12):1343-52. PubMed ID: 18951208
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Epithelial ovarian carcinoma of low malignant potential.
    Barnhill D; Heller P; Brzozowski P; Advani H; Gallup D; Park R
    Obstet Gynecol; 1985 Jan; 65(1):53-9. PubMed ID: 2981419
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognosis and management of borderline tumours of the ovary.
    Tropé C; Kaern J
    Curr Opin Obstet Gynecol; 1996 Feb; 8(1):12-6. PubMed ID: 8777251
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Endometriosis-associated ovarian carcinoma (EAOC): an entity distinct from other ovarian carcinomas as suggested by a nested case-control study.
    Erzen M; Rakar S; Klancnik B; Syrjänen K
    Gynecol Oncol; 2001 Oct; 83(1):100-8. PubMed ID: 11585420
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Isolated lymph node relapse of epithelial ovarian carcinoma: outcomes and prognostic factors.
    Blanchard P; Plantade A; Pagès C; Afchain P; Louvet C; Tournigand C; de Gramont A
    Gynecol Oncol; 2007 Jan; 104(1):41-5. PubMed ID: 16952391
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.